SG Americas Securities
ABUS icon

SG Americas Securities’s Arbutus Biopharma ABUS Stock Holding History

SG Americas Securities’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Buy
224,894
+145,861
+185% +$640K ﹤0.01% 1834
2026
Q1 		$356K Buy
79,033
+37,395
+90% +$164K ﹤0.01% 2367
2025
Q4 		$200K Buy
41,638
+18,265
+78% +$82.1K ﹤0.01% 2930
2025
Q3 		$106K Sell
23,373
-3
-0% -$11 ﹤0.01% 3055
2025
Q2 		$72K Sell
23,376
-26,594
-53% -$88.3K ﹤0.01% 2701
2025
Q1 		$174K Sell
49,970
-19,149
-28% -$63.9K ﹤0.01% 2630
2024
Q4 		$226K Buy
69,119
+16,250
+31% +$59.8K ﹤0.01% 2033
2024
Q3 		$204K Buy
+52,869
New +$203K ﹤0.01% 2478
2024
Q2 		– Sell
-19,644
Closed -$51K – 2798
2024
Q1 		$51K Sell
19,644
-26,528
-57% -$68.7K ﹤0.01% 2765
2023
Q4 		$115K Buy
46,172
+6,117
+15% +$12K ﹤0.01% 2653
2023
Q3 		$81K Buy
+40,055
New +$84K ﹤0.01% 2846
2023
Q2 		– Sell
-52,397
Closed -$159K – 2219
2023
Q1 		$159K Buy
52,397
+27,016
+106% +$76.2K ﹤0.01% 2593
2022
Q4 		$59K Sell
25,381
-4,094
-14% -$9.79K ﹤0.01% 2823
2022
Q3 		$56K Buy
29,475
+7,957
+37% +$18.7K ﹤0.01% 2976
2022
Q2 		$58K Buy
21,518
+8,274
+62% +$21.2K ﹤0.01% 3245
2022
Q1 		$39K Sell
13,244
-8,381
-39% -$25.7K ﹤0.01% 2856
2021
Q4 		$84K Sell
21,625
-577,724
-96% -$2.24M ﹤0.01% 3119
2021
Q3 		$2.57M Buy
+599,349
New +$2M 0.01% 1049
2019
Q4 		– Sell
-35,701
Closed -$54K – 3255
2019
Q3 		$54K Sell
35,701
-37,397
-51% -$64.4K ﹤0.01% 2804
2019
Q2 		$152K Buy
73,098
+15,644
+27% +$40K ﹤0.01% 2575
2019
Q1 		$206K Buy
57,454
+9,078
+19% +$34.9K ﹤0.01% 2545
2018
Q4 		$185K Sell
48,376
-56,480
-54% -$278K ﹤0.01% 2427
2018
Q3 		$991K Buy
+104,856
New +$1.04M 0.01% 1691

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SG Americas Securities's ABUS Position: Q2 2026 in Review

SG Americas Securities increased its Arbutus Biopharma (ABUS) stake by 185% in Q2 2026, buying an estimated $640K and bringing the position to 224,894 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1834.

SG Americas Securities first reported a position in ABUS in Q3 2018 and has held it in 23 quarters since. The position peaked at $2.57M in Q3 2021. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • SG Americas Securities held 224,894 shares of Arbutus Biopharma worth $1.08M as of Q2 2026.
  • SG Americas Securities bought 145,861 Arbutus Biopharma shares in Q2 2026, an estimated $640K.
  • Arbutus Biopharma made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1834 holding.
  • SG Americas Securities first reported a position in Arbutus Biopharma in Q3 2018 and has held it in 23 quarters since.
  • SG Americas Securities's Arbutus Biopharma position peaked at $2.57M in Q3 2021.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.